跳至主要内容
临床试验/NCT01301586
NCT01301586Unknown1 期

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF A NOVEL ORAL ACNE TREATMENT FOR THE TREATMENT OF ACNE VULGARIS

Nexgen Dermatologics, Inc.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2010年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
入组人数
60
试验地点
2
主要终点
The mean number of Inflammatory Lesions on the face at the beginning and end of treatment

研究概览

简要总结

The purpose of this study is to evaluate a novel, combination product for the treatment of acne vulgaris in females

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
13 Years 至 60 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy females 13 years of age or older
  • Non-pregnant, non-lactating females
  • Signed written informed consent form
  • Must be able to understand and be willing to follow all study instructions
  • Have a clinical diagnosis of acne vulgaris

排除标准

  • Female subjects who are pregnant or nursing
  • Any concomitant dermatologic condition that may affect outcome measures
  • Concurrent use of any other medication to treat acne vulgaris
  • Have a history or clinical evidence of any other active acute or chronic medical disease or condition considered by the principal investigator as unsuitable for the study
  • Are currently using any other investigational agent or device
  • Have participated in any other clinical study within 90 days prior to enrollment
  • Employees or family members of sponsor or research site

研究组 & 干预措施

Oral antibiotic plus soy extract

Active Comparator

干预措施: Doxycycline and S-equol (Drug)

Oral antibiotic

Active Comparator

干预措施: Doxycycline (Drug)

结局指标

主要结局

The mean number of Inflammatory Lesions on the face at the beginning and end of treatment

时间窗: 12 weeks

The number of inflammatory lesions will be counted by a trained investigator at the beginning and end of treatment.

次要结局

  • The mean number of Comedones will be evaluated at the beginning and end of treatment(12 weeks)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

A Novel Combination Oral Agent to Treat Acne Vulgaris | 临床试验